Pharmacologic Management of Comorbid Obsessive‑Compulsive Disorder and Anorexia Nervosa

First‑Line SSRI Therapy

Fluoxetine 60 mg daily is the preferred first‑line agent because it has the strongest evidence for efficacy in both bulimia‑type eating disorders (Level 1C recommendation) and obsessive‑compulsive disorder, and higher doses are required for OCD symptom control【@2】.
All SSRIs require higher‑than‑typical dosing for OCD; initiating treatment at doses above those used for depression improves therapeutic response【@1】【@3】.
If fluoxetine cannot be used, other SSRIs (sertraline, paroxetine, fluvoxamine, escitalopram) are acceptable provided they are titrated to the upper end of their dosing range【@1】【@3】【@4】.
Treatment response should be evaluated after 8–12 weeks, although early signs of improvement may appear as early as 2–4 weeks【@3】【@4】.

SSRIs have minimal evidence for treating anorexia nervosa itself; the American Psychiatric Association guideline recommends psychotherapy and weight restoration rather than pharmacotherapy for AN【@2】. In comorbid cases, the SSRI targets OCD while psychotherapy addresses the eating‑disorder component.

Clomipramine is recommended after an adequate SSRI trial (8–12 weeks at maximum tolerated dose); head‑to‑head trials show efficacy comparable to SSRIs for OCD【@1】【@3】.
Clomipramine’s lower tolerability (e.g., anticholinergic side effects) limits its use as a first‑line option【@1】【@3】.
Cardiac monitoring (baseline and periodic ECG) is required because clomipramine can prolong the QTc interval【@2】.

Atypical antipsychotics (e.g., risperidone, aripiprazole) are the established augmentation strategy when SSRI monotherapy is insufficient after 8–12 weeks【@3】.
In patients with anorexia nervosa, augmentation requires careful metabolic and weight monitoring due to the risk of further weight loss and other metabolic effects【@2】.

Initiate an SSRI (fluoxetine 60 mg daily preferred)【@1】【@2】.
Start eating‑disorder‑focused psychotherapy concurrently – family‑based treatment for adolescents/young adults and individual CBT for adults【@2】.
Add exposure and response prevention (ERP) for OCD symptoms【@1】【@4】.
Re‑assess at 8–12 weeks: continue and optimize dose if there is a partial response; switch to another SSRI or clomipramine if response is minimal【@3】【@4】.
If inadequate after a second pharmacologic agent, augment with an atypical antipsychotic【@3】.
Maintain pharmacotherapy for at least 12–24 months after remission because of the high risk of OCD relapse【@3】【@4】.

Baseline assessments: ECG (especially if purging behaviors are present or clomipramine is considered), comprehensive metabolic panel, CBC, liver and renal function tests, and vital signs including orthostatic measurements【@2】.
Ongoing monitoring: body weight, vital signs, SSRI‑related adverse effects (gastro‑intestinal symptoms, sexual dysfunction, activation), and treatment adherence【@1】【@3】【@2】.

Fluoxetine 60 mg daily is recommended as the initial medication because it is the only SSRI approved by the FDA for an eating disorder (bulimia nervosa), has the strongest efficacy data for OCD at this dose, and is effective for generalized anxiety disorder. [1][2]
For patients with anorexia nervosa, SSRIs (including fluoxetine) have minimal evidence for promoting weight restoration or acute symptom improvement, but may help prevent relapse after weight restoration and can address comorbid anxiety/OCD symptoms. [1][2]

The American Psychiatric Association advises that medication should not be the primary treatment for anorexia nervosa; eating‑disorder‑focused psychotherapy with weight restoration is the cornerstone of care. [1][2]
In adults with anorexia nervosa, initiate individual psychotherapy that normalizes eating behaviors, restores weight, and addresses fear of weight gain and body‑image disturbance. [1][2]
For adolescents and emerging adults, family‑based treatment involving caregivers is the recommended approach. [1][2]

Prior to starting fluoxetine, obtain an electrocardiogram (ECG), comprehensive metabolic panel, complete blood count, liver and renal function tests, and orthostatic vital signs. [1][2]
ECG monitoring is essential because patients with restrictive eating disorders are at heightened risk for QTc prolongation, especially when purging behaviors or electrolyte abnormalities are present. [1][2]
Throughout treatment, regularly track weight, vital signs, and orthostatic changes to detect clinical deterioration early. [1][2]

OCD requires higher‑than‑typical antidepressant dosing; a 60 mg fluoxetine dose is critical because lower doses often fail to control obsessive‑compulsive symptoms. [3][4]
If a patient shows minimal or no response after 8–12 weeks at the maximum tolerated fluoxetine dose, switch to another SSRI (e.g., sertraline, paroxetine, fluvoxamine, escitalopram) at the upper end of its dosing range. [3][4]
An alternative to another SSRI is clomipramine, which has efficacy comparable to SSRIs for OCD but necessitates cardiac monitoring due to QTc prolongation risk. [3][4]

When two adequate SSRI trials (including fluoxetine) fail after 8–12 weeks each at maximum tolerated doses, augment therapy with an atypical antipsychotic such as risperidone or aripiprazole. [3][4]
Clomipramine can also serve as a second‑line agent after SSRI failure; it offers efficacy similar to SSRIs but has lower tolerability because of anticholinergic side effects. [3][4]
Atypical antipsychotics are the established augmentation option for patients with treatment‑resistant OCD. [3][4]